Postnatal infant HIV prophylaxis: A survey of U.S. practice

AIDS Patient Care and STDs

Volumn 25, Issue 1, 2011, Pages 1-4

  McKeegan, Kathleen ^a   Rutstein, Richard ^a,b   Lowenthal, Elizabeth ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; FEMALE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; POSTNATAL CARE; PROPHYLAXIS; UNITED STATES;

ANTI-HIV AGENTS; DATA COLLECTION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; ODDS RATIO; RISK FACTORS; UNITED STATES; VIRAL LOAD;

EID: 78651285307     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0255     Document Type: Article

References (18)

1. Whitmore SK, Zhang X, Taylor AW. Estimated number of births to HIV+ women in the US, 2006. Conference on Retroviruses and Opportunistic Infections. Volume 924. Montreal, Canada: CROI; 2009.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 trans-mission. J Acquir Immune Defic Syndr 2002;29:484-494.
3. Whitmore SK, Patel-Larson A, Espinoza L, Ruffo NM, Rao S. Missed opportunities to prevent perinatal human immuno-deficiency virus transmission in 15 jurisdictions in the United States during 2005-2008. Women Health. 2010;50:414-425.
4. Schulte JDK, Sukalac T, Bohannon B, Fowler MG, for the Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2007;119:900-906.
5. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Anti-retroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010. pp. 1-90. http://aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf (Last accessed September 23 2010).
6. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-868.
7. Six Week Extended-Dose Nevirapine Study, Team. Ex-tended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: An analysis of three randomised con-trolled trials. Lancet 2008; 372: 300-313.
8. Lopriore E, Rozendaal L, Gelinck L, Bokenkamp R, Boelen C, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS 2007;121:2564-2565.
9. McArthur M, Kalu S, Foulks A, Aly A, Jain S, Patel J. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 2009;28:1127-1129.
10. de Ruiter A, Mercey D, Anderson J, et al. British HIV As-sociation and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452-502.
11. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview. Am J Med 1997;102:9-15.
12. Havens PL, American Academy of Pediatrics Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003;111(6 Pt 1):1475-1489.
13. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recom-mendations for postexposure prophylaxis. MMWR Recomm Rep 2005;54:1-17.
14. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285: 2083-2093.
15. Thorne C, Newell M-L. Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern? Drug Safety 2007;30:203-213.
16. Chadwick E, Pinto J, Yogev R, et al. Early initiation of lo-pinavir/ritonavir in infants less than 6 weeks of age: Phar-macokinetics and 24-week safety and efficacy. Pediatr Infect Dis J 2009;28:215-219.
17. Centers for Disease Control and Prevention. HIV Surveil-lance Report, 2008 Vol. 20. Published June 2010. http://www.cdc.gov/hiv/topics/surveillance/ resources/reports, accessed July 9, 2010.
18. Kaiser Family Foundation. Data Source: Centers for Disease Control and Prevention. Division of HIV/AIDS Prevention-Surveillance and Epidemiology, Special Data Request, February 2010. www.statehealthfacts.org. (Last accessed November 3, 2010).